Skip to main content
OpenTrials
Completed

NCT Number: NCT01909648

HbA2 Leuven and Its Impact on HbA1c Results

The study is designed to demonstrate HbA2 Leuven mutation and to asssess its impact on routine HbA1c measurements.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Family Study HbA2 Leuven Mutation.

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UZLeuven

Leuven, Belgium

About this study

HbA2 Leuven mutation will be investigated using molecular diagnostic techniques.

Interference on HbA1c measurements will be assessed in HbA2 Leuven carriers using different methodologies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Family history of HbA2 Leuven mutation.

Exclusion criteria

  • Any condition inhibiting simple blood withdrawal.

Treatment and study plan

blood withdrawal

Other

Other names: Impact of mutation on routine HbA1c measurements.

blood withdrawal

Genetic

Other names: Demonstration of HbA2 Leuven mutation

Primary outcomes

  1. Demonstration of presence/absence of HbA2 Leuven mutation

    Time frame: 1 year

Secondary outcomes

  1. Demonstration of impact of HbA2 Leuven mutation on routine HbA1c measurements

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Registry information

Acronym: HbA2 Leuven

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Jul 26, 2013
Registry last updated
Jul 7, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.